CTLT Stock Recent News
CTLT LATEST HEADLINES
Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catalent , saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.
CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.
Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on Monday.
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden. Financial details of the agreement, which is expected.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".
Catalent (CTLT) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.09 per share a year ago.
Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?